Given the favorable safety profile and promising efficacy, WX-0593 may potentially provide a new therapeutic option for Chinese advanced NSCLC patients with ALK or ROS1 rearrangement, thus contributing to reducing the treatment costs and increasing drug accessibility. Here, ROS1 is linked to non-small cell lung carcinoma.